Detecting unexpected growths in health technologies expenditures: the case of MIPRES in Colombia

• Published in: BMC health services research Vol. 23; no. 1; pp. 1 - 1153
• Main Authors: Espinosa, Oscar, Bejarano, Valeria, Sanabria, Cristian, Rodríguez, Jhonathan, Basto, Sergio, Rodríguez-Lesmes, Paul, Robayo, Adriana
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 25-10-2023; BioMed Central; BMC
• Subjects: Algorithms; Cost benefit analysis; Costs; Data analytics; Datasets; Economic aspects; Enteral nutritional; Evaluation; Expenditures; Health care industry; Health expenditures; Health technologies; High-cost technology; Information management; Information systems; Innovations; Managed competition; Medical economics; Medical equipment; Medical informatics; Medical technology; Monoclonal antibodies; Nutrition; Statistical data analysis; Technology; Time series; Colombia
• DOI: 10.1186/s12913-023-10155-w
• EISSN: 1472-6963

We developed an algorithm to explore unexpected growth in the usage and costs of health technologies. We exploit data from the expenditures on technologies funded by the Colombian government under the compulsory insurance system, where all prescriptions for technologies not included in an explicit list must be registered in a centralized information system, covering the period from 2017 to 2022. The algorithm consists of two steps: an outlier detection method based on the density of the expenditures for selecting a first set of technologies to consider (39 technologies out of 106,957), and two anomaly detection models for time series to determine which insurance companies, health providers, and regions have the most notorious increases. We have found that most medicines associated with atypical behavior and significant monetary growth could be linked to the use of recently introduced drugs in the market. These drugs have valid patents and very specific clinical indications, often involving high-cost pharmacological treatments. The most relevant case is the Burosumab, approved in 2018 to treat a rare genetic disorder affecting skeletal growth. Secondly, there is clear evidence of anomalous increasing trend evolutions in the identified enteral nutritional support supplements or Food for Special Medical Purposes. The health system did not purchase these products before July 2021, but in 2022 they represented more than 500,000 USD per month.